June 12, 2024 07:24 AM EDT

Ultragenyx touts Phase 2 data for Mereo-partnered rare bone disorder drug as Phase 3 gets underway

Katherine Lewin

News Reporter

Four years after betting up to $304 million on a drug for a rare genetic bone disorder, Ultragenyx and its partner Mereo BioPharma reported positive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ultragenyx touts Phase 2 data for Mereo-partnered rare bone disorder drug as Phase 3 gets underway

Katherine Lewin

News Reporter

Sign up to read this article for free.

Exclusive: Two Vida Ventures co-founders exit the VC firm

Cases of severe RSV in two Moderna vaccine candidates' trials raise questions about future

Early data on BTK degraders suggest promise of next-gen approach

Roche initially didn't want to buy Poseida — and partner Astellas didn't submit an offer, new filings show

J&J, Legend’s Carvykti clears a type of blood cancer in ‘nine out of 10’ patients

The key to faster, more impactful research? Put patients in the driver’s seat

Ul­tragenyx touts Phase 2 da­ta for Mereo-part­nered rare bone dis­or­der drug as Phase 3 gets un­der­way

Katherine Lewin

News Reporter

Sign up to read this article for free.

Ex­clu­sive: Two Vi­da Ven­tures co-founders ex­it the VC firm

Cas­es of se­vere RSV in two Mod­er­na vac­cine can­di­dates' tri­als raise ques­tions about fu­ture

Ear­ly da­ta on BTK de­graders sug­gest promise of next-gen ap­proach

Roche ini­tial­ly did­n't want to buy Po­sei­da — and part­ner Astel­las did­n't sub­mit an of­fer, new fil­ings show

J&J, Leg­end’s Carvyk­ti clears a type of blood can­cer in ‘nine out of 10’ pa­tients

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

Ultragenyx touts Phase 2 data for Mereo-partnered rare bone disorder drug as Phase 3 gets underway

Exclusive: Two Vida Ventures co-founders exit the VC firm

Cases of severe RSV in two Moderna vaccine candidates' trials raise questions about future

Early data on BTK degraders suggest promise of next-gen approach

Roche initially didn't want to buy Poseida — and partner Astellas didn't submit an offer, new filings show

J&J, Legend’s Carvykti clears a type of blood cancer in ‘nine out of 10’ patients

The key to faster, more impactful research? Put patients in the driver’s seat